4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Gynecomastia by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 2 ongoing clinical trials involving Gynecomastia
Of the 2 trials,1 trials are in Phase III
Furthermore, 1 trials are in Phase II

Number of ongoing Clinical Trials (for drugs) involving Gynecomastia by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Gynecomastia, a male health condition. North America, and Middle East and Africa are among some of the other prominent regions engaged in Gynecomastia-related drug trials.

Gynecomastia related clinical trial sponsors

Icahn School of Medicine at Mount Sinai, and University of Tanta are among the notable clinical trial sponsors involved in Gynecomastia. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Gynecomastia

Tamoxifen Citrate (Nolvadex, Nolvadex-D), Bromocriptine mesylate (Parlodel), and
Danazol (Danol/Cyclomen/Danatrol/Ladogal/Danocrine/Bonzole) are among the key marketed drugs involving Gynecomastia.

Tamoxifen Citrate (Nolvadex, Nolvadex-D) is a nonsteroidal antiestrogen selective estrogen receptor modulators (SERM) with tissue-specific activities. It functions via Estrogen Receptor (ESR) Antagonist mechanism of action. Tamoxifen Citrate is formulated as tablets, coated tablets, and film-coated tablets for oral route of administration. Tamoxifen Citrate is indicated for the treatment of metastatic breast cancer, adjuvant treatment of breast cancer, ductal carcinoma in situ (DCIS), for reducing breast cancer incidence in high-risk women, treatment of anovulatory infertility, and also indicated for treatment of gynecomastia of mastalgia caused by antiandrogens in the monotherapy treatment of prostate carcinoma. Tamoxifen Citrate was first approved in 1974 and is marketed globally including the US, the UK, Australia, France, Germany, and Japan by AstraZeneca Plc and its subsidiaries.

Bromocriptine mesylate (Parlodel) is a semisynthetic ergotamine derivative acts as anti-parkinson agent. It functions via D2 Dopamine Receptor (Dopamine D2 Receptor or DRD2) Agonist Mechanism of action. It is formulated as tablets and hard gelatin capsules for oral administration. Bromocriptine mesylate is marketed for the treatment of Gynecomastia and several other indications including Parkinson's Disease, Women Infertility, Adenomas, Polycystic Ovarian Syndrome, Amenorrhea, Male Hypogonadism, Acromegaly, Female Hypogonadism, Galactorrhea, Gynecomastia, Hyperprolactinaemia, Postencephalitic Parkinsonism, Premenstrual Syndrome, and Secondary Amenorrhea. Bromocriptine mesylate Citrate was first approved in 1975 and is marketed globally including the US, the UK, Australia, France, Germany, and Japan by several global pharma giants including Validus Pharmaceuticals LLC, Novartis Pharmaceuticals Australia Pty Ltd, Mylan EPD sprl, and Meda Pharma SAU.